Community-Acquired Bacterial Pneumonia – Epidemiology – Mature Markets Data
Clarivate Epidemiology’s coverage of community-acquired bacterial pneumonia (CABP) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the event rate of CABP for each country, as well as annualized event counts projected to the national population.
Clarivate Epidemiology’s CABP forecast will answer the following questions:
- Of all people diagnosed with CABP, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CABP over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
In addition to the total number of events for each forecast year, Clarivate Epidemiology provides at least ten years of forecast data for the following CABP subpopulations:
- Diagnosed inpatient events by drug-treatment status.
- Diagnosed outpatient events by drug-treatment status.
Table of contents
- Community-Acquired Bacterial Pneumonia - Epidemiology - Mature Markets Data
- Introduction
- Key Findings
- Event Rate of Community-Acquired Bacterial Pneumonia per 1,000 Among People of All Ages in 2021 and 2031
- Event Rate of Community-Acquired Bacterial Pneumonia per 1,000 Among People of All Ages in 2021 and 2031
- Relative Sizes of the Factors Contributing to the Trend in Events of Community-Acquired Bacterial Pneumonia over the Next Ten Years
- Relative Sizes of the Contributing Factors to the Trend in Events of Community-Acquired Bacterial Pneumonia over the Next Ten Years
- Epidemiology Data
- Methods
- Reference Materials
- Introduction
Utsav Patel, M.P.H., is an associate epidemiologist at Clarivate. His areas of interest are cardiovascular diseases and cancer epidemiology. Previously, he worked as a graduate research assistant at City University of New York, where he conducted multi-omics investigations into cancer study funded by the National Institutes of Health. He obtained his M.P.H. in epidemiology and biostatistics from City University of New York.
Thomas J. Arndt, M.P.H., C.P.H., is a senior epidemiologist at Clarivate. He earned his master’s degree in public health at the University of Florida, where he conducted an internship developing a clinical model for noninvasively screening for nonalcoholic steatohepatitis (NASH). He also holds a B.S. in microbiology and cell science and a B.A. in Spanish, both from the University of Florida. While studying at the University of Florida, Mr. Arndt worked in two physiology-based research labs focusing on maternal and fetal stresses during pregnancy and parturition.